Published in Cancer Res on September 01, 2006
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci U S A (2007) 1.87
DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog (2008) 1.67
Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol (2007) 1.64
Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling. Cell Cycle (2011) 1.54
Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest (2009) 1.22
Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation. Proc Natl Acad Sci U S A (2012) 1.16
Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer (2009) 1.14
The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. Cancer Cell (2009) 1.14
p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene (2009) 1.12
Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res (2008) 1.09
Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. PLoS One (2009) 1.08
Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One (2008) 1.08
Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. J Biol Chem (2008) 1.05
Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). Int J Oncol (2012) 1.05
Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One (2009) 1.05
Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion. J Biol Chem (2009) 1.02
Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci U S A (2011) 1.00
Tensin 2 modulates cell contractility in 3D collagen gels through the RhoGAP DLC1. J Cell Biochem (2010) 0.96
DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol Biol Cell (2009) 0.94
DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res (2011) 0.93
Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A. J Biol Chem (2014) 0.92
CDK5 is a major regulator of the tumor suppressor DLC1. J Cell Biol (2014) 0.89
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. PLoS One (2013) 0.89
Deleted in liver cancer protein family in human malignancies (Review). Oncol Lett (2011) 0.89
DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity. Mol Cell Biol (2012) 0.88
Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphoma. BMC Genet (2009) 0.84
Caveolin-1 protects B6129 mice against Helicobacter pylori gastritis. PLoS Pathog (2013) 0.84
Tensin4 is up-regulated by EGF-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. Oncotarget (2015) 0.83
The RhoGAP protein Deleted in Liver Cancer 3 (DLC3) is essential for adherens junctions integrity. Oncogenesis (2012) 0.83
C1-Ten is a protein tyrosine phosphatase of insulin receptor substrate 1 (IRS-1), regulating IRS-1 stability and muscle atrophy. Mol Cell Biol (2013) 0.83
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma. Int J Mol Sci (2011) 0.81
The protein-tyrosine kinase Syk interacts with the C-terminal region of tensin2. Biochim Biophys Acta (2011) 0.81
Solution structure of tensin2 SH2 domain and its phosphotyrosine-independent interaction with DLC-1. PLoS One (2011) 0.80
Tensin1 positively regulates RhoA activity through its interaction with DLC1. Biochim Biophys Acta (2015) 0.80
Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene. Mol Diagn Ther (2014) 0.79
PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Nat Commun (2013) 0.79
Deleted in liver cancer-1 inhibits cell growth and tumorigenicity in human pancreatic cancer. Oncol Lett (2013) 0.78
Uncovering the rare variants of DLC1 isoform 1 and their functional effects in a Chinese sporadic congenital heart disease cohort. PLoS One (2014) 0.78
Down-regulation of tensin2 enhances tumorigenicity and is associated with a variety of cancers. Oncotarget (2016) 0.77
The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity. BMC Cancer (2015) 0.77
Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode. J Biol Chem (2012) 0.76
Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PLoS One (2011) 0.76
Dlc1 interaction with non-muscle myosin heavy chain II-A (Myh9) and Rac1 activation. Biol Open (2016) 0.75
Functional validation of tensin2 SH2-PTB domain by CRISPR/Cas9-mediated genome editing. J Vet Med Sci (2016) 0.75
Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology (2007) 5.75
Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem (2002) 3.48
An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med (2008) 2.68
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A (2008) 2.33
Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA. J Biol Chem (2007) 2.20
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A (2011) 2.17
Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol (2010) 1.97
MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology (2010) 1.88
Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res (2003) 1.87
The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology (2010) 1.85
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (2004) 1.83
Precursor microRNA-programmed silencing complex assembly pathways in mammals. Mol Cell (2012) 1.81
Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases. Ann Surg (2004) 1.79
Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol (2002) 1.75
Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res (2005) 1.73
Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int (2011) 1.60
Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem (2003) 1.55
Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology (2012) 1.55
Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery (2005) 1.54
Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res (2002) 1.53
AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res (2012) 1.52
Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology (2010) 1.52
Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol (2013) 1.46
Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl (2003) 1.44
Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg (2005) 1.44
Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci U S A (2005) 1.40
Natural occurrence and characterization of two internal ribosome entry site elements in a novel virus, canine picodicistrovirus, in the picornavirus-like superfamily. J Virol (2011) 1.39
HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene (2005) 1.34
Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology (2009) 1.34
CREB--a real culprit in oncogenesis. FEBS J (2007) 1.33
Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology (2006) 1.33
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg (2003) 1.27
Thiol peroxidases mediate specific genome-wide regulation of gene expression in response to hydrogen peroxide. Proc Natl Acad Sci U S A (2011) 1.26
Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J Biol Chem (2009) 1.25
Cooperation of yeast peroxiredoxins Tsa1p and Tsa2p in the cellular defense against oxidative and nitrosative stress. J Biol Chem (2001) 1.25
Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer (2003) 1.24
Peroxiredoxin-null yeast cells are hypersensitive to oxidative stress and are genomically unstable. J Biol Chem (2004) 1.23
Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One (2011) 1.22
Nuclear localization of the cell cycle regulator CDH1 and its regulation by phosphorylation. J Biol Chem (2003) 1.22
The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucleic Acids Res (2005) 1.21
The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response. Cell Host Microbe (2011) 1.21
D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Exp Biol Med (Maywood) (2010) 1.19
Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology (2007) 1.18
Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg (2003) 1.17
Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res (2006) 1.17
P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res (2007) 1.17
TORC1 and TORC2 coactivators are required for tax activation of the human T-cell leukemia virus type 1 long terminal repeats. J Virol (2006) 1.17
Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun (2007) 1.14
Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology (2012) 1.13
Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol (2002) 1.11
Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J Virol (2006) 1.11
Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS One (2011) 1.11
Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci U S A (2014) 1.11
Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol (2003) 1.10
Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology (2014) 1.08
The pathological roles of BART miRNAs in nasopharyngeal carcinoma. J Pathol (2012) 1.08
Human T-cell leukemia virus oncoprotein tax represses nuclear receptor-dependent transcription by targeting coactivator TAX1BP1. Cancer Res (2007) 1.07
Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology (2012) 1.06
Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One (2009) 1.05
Liver transplantation for combined hepatocellular cholangiocarcinoma. Asian J Surg (2007) 1.04
Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res (2005) 1.03
Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol (2012) 1.03
Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res (2011) 1.02
The retroviral oncoprotein Tax targets the coiled-coil centrosomal protein TAX1BP2 to induce centrosome overduplication. Nat Cell Biol (2006) 1.02
Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol (2013) 1.02
Small interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication. PLoS One (2009) 1.02
High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol (2004) 1.01
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res (2004) 1.01
High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer (2002) 1.01
siRNA and shRNA screens advance key understanding of host factors required for HIV-1 replication. Retrovirology (2009) 1.01
Influenza A virus NS1 protein does not suppress RNA interference in mammalian cells. J Gen Virol (2006) 1.00
Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Lett (2005) 1.00
Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology (2006) 1.00
Regulation of hepatocarcinogenesis by microRNAs. Front Biosci (Elite Ed) (2013) 1.00
Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood (2011) 0.99
Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One (2011) 0.99
Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol (2004) 0.99
MIP-T3 is a negative regulator of innate type I IFN response. J Immunol (2011) 0.98
RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway. Hepatology (2013) 0.98
Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst (2012) 0.98
Hepatic resection for bilobar hepatocellular carcinoma: is it justified? Arch Surg (2003) 0.98
Specific TATAA and bZIP requirements suggest that HTLV-I Tax has transcriptional activity subsequent to the assembly of an initiation complex. Retrovirology (2004) 0.98